HomeCompareLDXHF vs EPRT

LDXHF vs EPRT: Dividend Comparison 2026

LDXHF yields 1238.39% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LDXHF wins by $124493861.48M in total portfolio value
10 years
LDXHF
LDXHF
● Live price
1238.39%
Share price
$0.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$124493861.54M
Annual income
$107,429,031,462,338.22
Full LDXHF calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — LDXHF vs EPRT

📍 LDXHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLDXHFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LDXHF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LDXHF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LDXHF
Annual income on $10K today (after 15% tax)
$105,263.16/yr
After 10yr DRIP, annual income (after tax)
$91,314,676,742,987.48/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, LDXHF beats the other by $91,314,676,731,792.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LDXHF + EPRT for your $10,000?

LDXHF: 50%EPRT: 50%
100% EPRT50/50100% LDXHF
Portfolio after 10yr
$62246930.80M
Annual income
$53,714,515,737,754.54/yr
Blended yield
86.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

LDXHF
No analyst data
Altman Z
-3.3
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LDXHF buys
0
EPRT buys
0
No recent congressional trades found for LDXHF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLDXHFEPRT
Forward yield1238.39%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$124493861.54M$64.3K
Annual income after 10y$107,429,031,462,338.22$13,170.85
Total dividends collected$123225412.32M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: LDXHF vs EPRT ($10,000, DRIP)

YearLDXHF PortfolioLDXHF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$134,539$123,839.01$11,212$512.01+$123.3KLDXHF
2$1,701,076$1,557,119.40$12,689$692.09+$1.69MLDXHF
3$20,219,975$18,399,823.95$14,521$944.30+$20.21MLDXHF
4$226,038,135$204,402,761.69$16,841$1,302.88+$226.02MLDXHF
5$2,377,382,925$2,135,522,120.49$19,841$1,821.64+$2377.36MLDXHF
6$23,535,021,639$20,991,221,908.63$23,818$2,587.47+$23535.00MLDXHF
7$219,391,496,761$194,209,023,607.94$29,230$3,744.65+$219391.47MLDXHF
8$1,926,711,724,815$1,691,962,823,279.82$36,816$5,540.38+$1926711.69MLDXHF
9$15,948,439,325,295$13,886,857,779,743.26$47,806$8,413.17+$15948439.28MLDXHF
10$124,493,861,540,404$107,429,031,462,338.22$64,324$13,170.85+$124493861.48MLDXHF

LDXHF vs EPRT: Complete Analysis 2026

LDXHFStock

Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.

Full LDXHF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this LDXHF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LDXHF vs SCHDLDXHF vs JEPILDXHF vs OLDXHF vs KOLDXHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.